nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—UGT1A9—Sorafenib—thyroid cancer	0.395	0.55	CbGbCtD
Ezogabine—UGT1A1—Sorafenib—thyroid cancer	0.323	0.45	CbGbCtD
Ezogabine—Renal colic—Vandetanib—thyroid cancer	0.0369	0.133	CcSEcCtD
Ezogabine—Chromaturia—Vandetanib—thyroid cancer	0.016	0.0576	CcSEcCtD
Ezogabine—Balance disorder—Vandetanib—thyroid cancer	0.0104	0.0376	CcSEcCtD
Ezogabine—Nephrolithiasis—Vandetanib—thyroid cancer	0.0071	0.0256	CcSEcCtD
Ezogabine—Influenza—Vandetanib—thyroid cancer	0.00358	0.0129	CcSEcCtD
Ezogabine—Dysphagia—Vandetanib—thyroid cancer	0.00358	0.0129	CcSEcCtD
Ezogabine—Neutropenia—Vandetanib—thyroid cancer	0.00335	0.0121	CcSEcCtD
Ezogabine—Dysuria—Vandetanib—thyroid cancer	0.00335	0.0121	CcSEcCtD
Ezogabine—Infestation NOS—Vandetanib—thyroid cancer	0.00319	0.0115	CcSEcCtD
Ezogabine—Infestation—Vandetanib—thyroid cancer	0.00319	0.0115	CcSEcCtD
Ezogabine—Haematuria—Vandetanib—thyroid cancer	0.00304	0.011	CcSEcCtD
Ezogabine—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00302	0.0109	CcSEcCtD
Ezogabine—Urinary tract disorder—Vandetanib—thyroid cancer	0.00283	0.0102	CcSEcCtD
Ezogabine—Urethral disorder—Vandetanib—thyroid cancer	0.00281	0.0101	CcSEcCtD
Ezogabine—Visual impairment—Vandetanib—thyroid cancer	0.00276	0.00996	CcSEcCtD
Ezogabine—Eye disorder—Vandetanib—thyroid cancer	0.00268	0.00966	CcSEcCtD
Ezogabine—Alopecia—Vandetanib—thyroid cancer	0.00253	0.00913	CcSEcCtD
Ezogabine—Mental disorder—Vandetanib—thyroid cancer	0.00251	0.00905	CcSEcCtD
Ezogabine—Malnutrition—Vandetanib—thyroid cancer	0.00249	0.009	CcSEcCtD
Ezogabine—Dysphagia—Sorafenib—thyroid cancer	0.00241	0.00871	CcSEcCtD
Ezogabine—Muscle spasms—Vandetanib—thyroid cancer	0.0024	0.00865	CcSEcCtD
Ezogabine—Vision blurred—Vandetanib—thyroid cancer	0.00235	0.00848	CcSEcCtD
Ezogabine—Tremor—Vandetanib—thyroid cancer	0.00234	0.00843	CcSEcCtD
Ezogabine—Neutropenia—Sorafenib—thyroid cancer	0.00226	0.00815	CcSEcCtD
Ezogabine—Loss of consciousness—Vandetanib—thyroid cancer	0.00219	0.00791	CcSEcCtD
Ezogabine—Infestation—Sorafenib—thyroid cancer	0.00215	0.00777	CcSEcCtD
Ezogabine—Infestation NOS—Sorafenib—thyroid cancer	0.00215	0.00777	CcSEcCtD
Ezogabine—Anxiety—Vandetanib—thyroid cancer	0.00212	0.00763	CcSEcCtD
Ezogabine—Hypokinesia—Epirubicin—thyroid cancer	0.00211	0.0076	CcSEcCtD
Ezogabine—Dry mouth—Vandetanib—thyroid cancer	0.00208	0.00749	CcSEcCtD
Ezogabine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00204	0.00735	CcSEcCtD
Ezogabine—Infection—Vandetanib—thyroid cancer	0.00202	0.00729	CcSEcCtD
Ezogabine—Nervous system disorder—Vandetanib—thyroid cancer	0.002	0.0072	CcSEcCtD
Ezogabine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00199	0.00719	CcSEcCtD
Ezogabine—Nystagmus—Epirubicin—thyroid cancer	0.00199	0.00718	CcSEcCtD
Ezogabine—Hypokinesia—Doxorubicin—thyroid cancer	0.00195	0.00703	CcSEcCtD
Ezogabine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00191	0.00689	CcSEcCtD
Ezogabine—Urethral disorder—Sorafenib—thyroid cancer	0.00189	0.00683	CcSEcCtD
Ezogabine—Nystagmus—Doxorubicin—thyroid cancer	0.00184	0.00665	CcSEcCtD
Ezogabine—Paraesthesia—Vandetanib—thyroid cancer	0.00183	0.00659	CcSEcCtD
Ezogabine—Dyspnoea—Vandetanib—thyroid cancer	0.00181	0.00655	CcSEcCtD
Ezogabine—Dyspepsia—Vandetanib—thyroid cancer	0.00179	0.00646	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00176	0.00634	CcSEcCtD
Ezogabine—Fatigue—Vandetanib—thyroid cancer	0.00175	0.00633	CcSEcCtD
Ezogabine—Constipation—Vandetanib—thyroid cancer	0.00174	0.00628	CcSEcCtD
Ezogabine—Alopecia—Sorafenib—thyroid cancer	0.00171	0.00616	CcSEcCtD
Ezogabine—Mental disorder—Sorafenib—thyroid cancer	0.00169	0.00611	CcSEcCtD
Ezogabine—Malnutrition—Sorafenib—thyroid cancer	0.00168	0.00607	CcSEcCtD
Ezogabine—Muscle spasms—Sorafenib—thyroid cancer	0.00162	0.00584	CcSEcCtD
Ezogabine—Skin discolouration—Epirubicin—thyroid cancer	0.00157	0.00568	CcSEcCtD
Ezogabine—Syncope—Sorafenib—thyroid cancer	0.00151	0.00544	CcSEcCtD
Ezogabine—Leukopenia—Sorafenib—thyroid cancer	0.00151	0.00543	CcSEcCtD
Ezogabine—Dysarthria—Epirubicin—thyroid cancer	0.0015	0.00542	CcSEcCtD
Ezogabine—Loss of consciousness—Sorafenib—thyroid cancer	0.00148	0.00533	CcSEcCtD
Ezogabine—Asthenia—Vandetanib—thyroid cancer	0.00146	0.00527	CcSEcCtD
Ezogabine—Gait disturbance—Epirubicin—thyroid cancer	0.00146	0.00526	CcSEcCtD
Ezogabine—Skin discolouration—Doxorubicin—thyroid cancer	0.00146	0.00526	CcSEcCtD
Ezogabine—Coordination abnormal—Epirubicin—thyroid cancer	0.00145	0.00522	CcSEcCtD
Ezogabine—Dry mouth—Sorafenib—thyroid cancer	0.0014	0.00505	CcSEcCtD
Ezogabine—Dysarthria—Doxorubicin—thyroid cancer	0.00139	0.00502	CcSEcCtD
Ezogabine—Infection—Sorafenib—thyroid cancer	0.00136	0.00492	CcSEcCtD
Ezogabine—Shock—Sorafenib—thyroid cancer	0.00135	0.00487	CcSEcCtD
Ezogabine—Gait disturbance—Doxorubicin—thyroid cancer	0.00135	0.00486	CcSEcCtD
Ezogabine—Nervous system disorder—Sorafenib—thyroid cancer	0.00135	0.00486	CcSEcCtD
Ezogabine—Dizziness—Vandetanib—thyroid cancer	0.00135	0.00486	CcSEcCtD
Ezogabine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00134	0.00485	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—thyroid cancer	0.00134	0.00483	CcSEcCtD
Ezogabine—Coma—Epirubicin—thyroid cancer	0.0013	0.00469	CcSEcCtD
Ezogabine—Rash—Vandetanib—thyroid cancer	0.00128	0.00463	CcSEcCtD
Ezogabine—Dermatitis—Vandetanib—thyroid cancer	0.00128	0.00463	CcSEcCtD
Ezogabine—Dyspnoea—Sorafenib—thyroid cancer	0.00122	0.00442	CcSEcCtD
Ezogabine—Nausea—Vandetanib—thyroid cancer	0.00121	0.00436	CcSEcCtD
Ezogabine—Dyspepsia—Sorafenib—thyroid cancer	0.00121	0.00436	CcSEcCtD
Ezogabine—Coma—Doxorubicin—thyroid cancer	0.0012	0.00434	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00119	0.00428	CcSEcCtD
Ezogabine—Fatigue—Sorafenib—thyroid cancer	0.00118	0.00427	CcSEcCtD
Ezogabine—Constipation—Sorafenib—thyroid cancer	0.00117	0.00424	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—thyroid cancer	0.0011	0.00396	CcSEcCtD
Ezogabine—Diplopia—Epirubicin—thyroid cancer	0.00103	0.00372	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—thyroid cancer	0.00103	0.00372	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—thyroid cancer	0.00102	0.00367	CcSEcCtD
Ezogabine—Asthenia—Sorafenib—thyroid cancer	0.000985	0.00355	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—thyroid cancer	0.000955	0.00345	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—thyroid cancer	0.000955	0.00345	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—thyroid cancer	0.000953	0.00344	CcSEcCtD
Ezogabine—Dizziness—Sorafenib—thyroid cancer	0.000908	0.00328	CcSEcCtD
Ezogabine—Influenza—Epirubicin—thyroid cancer	0.000892	0.00322	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—thyroid cancer	0.000892	0.00322	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000882	0.00318	CcSEcCtD
Ezogabine—Rash—Sorafenib—thyroid cancer	0.000866	0.00312	CcSEcCtD
Ezogabine—Dermatitis—Sorafenib—thyroid cancer	0.000865	0.00312	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—thyroid cancer	0.000834	0.00301	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—thyroid cancer	0.000834	0.00301	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—thyroid cancer	0.000826	0.00298	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—thyroid cancer	0.000826	0.00298	CcSEcCtD
Ezogabine—Nausea—Sorafenib—thyroid cancer	0.000816	0.00294	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—thyroid cancer	0.000812	0.00293	CcSEcCtD
Ezogabine—Infestation—Epirubicin—thyroid cancer	0.000796	0.00287	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—thyroid cancer	0.000796	0.00287	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—thyroid cancer	0.000772	0.00279	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—thyroid cancer	0.000772	0.00279	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—thyroid cancer	0.000759	0.00274	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000752	0.00271	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—thyroid cancer	0.000751	0.00271	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—thyroid cancer	0.000736	0.00266	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—thyroid cancer	0.000736	0.00266	CcSEcCtD
Ezogabine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000705	0.00254	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—thyroid cancer	0.000704	0.00254	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—thyroid cancer	0.000702	0.00253	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—thyroid cancer	0.0007	0.00253	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000696	0.00251	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—thyroid cancer	0.000688	0.00248	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—thyroid cancer	0.000667	0.00241	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000653	0.00235	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000651	0.00235	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—thyroid cancer	0.000648	0.00234	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—thyroid cancer	0.000637	0.0023	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—thyroid cancer	0.000631	0.00228	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—thyroid cancer	0.000626	0.00226	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—thyroid cancer	0.000622	0.00224	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—thyroid cancer	0.000618	0.00223	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—thyroid cancer	0.000598	0.00216	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—thyroid cancer	0.000586	0.00211	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—thyroid cancer	0.000584	0.00211	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—thyroid cancer	0.000579	0.00209	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000577	0.00208	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—thyroid cancer	0.000575	0.00208	CcSEcCtD
Ezogabine—Malaise—Epirubicin—thyroid cancer	0.000561	0.00202	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—thyroid cancer	0.000559	0.00202	CcSEcCtD
Ezogabine—Syncope—Epirubicin—thyroid cancer	0.000558	0.00201	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—thyroid cancer	0.000557	0.00201	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—thyroid cancer	0.000553	0.002	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—thyroid cancer	0.000546	0.00197	CcSEcCtD
Ezogabine—Vision blurred—Doxorubicin—thyroid cancer	0.000542	0.00196	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000534	0.00193	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—thyroid cancer	0.000527	0.0019	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—thyroid cancer	0.000523	0.00189	CcSEcCtD
Ezogabine—Malaise—Doxorubicin—thyroid cancer	0.000519	0.00187	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—thyroid cancer	0.000518	0.00187	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—thyroid cancer	0.000517	0.00186	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—thyroid cancer	0.000516	0.00186	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—thyroid cancer	0.000515	0.00186	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—thyroid cancer	0.000512	0.00185	CcSEcCtD
Ezogabine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000506	0.00182	CcSEcCtD
Ezogabine—Infection—Epirubicin—thyroid cancer	0.000504	0.00182	CcSEcCtD
Ezogabine—Shock—Epirubicin—thyroid cancer	0.000499	0.0018	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—thyroid cancer	0.000498	0.0018	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000497	0.00179	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000491	0.00177	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—thyroid cancer	0.000488	0.00176	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—thyroid cancer	0.000484	0.00175	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—thyroid cancer	0.000479	0.00173	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—thyroid cancer	0.000473	0.00171	CcSEcCtD
Ezogabine—Infection—Doxorubicin—thyroid cancer	0.000466	0.00168	CcSEcCtD
Ezogabine—Shock—Doxorubicin—thyroid cancer	0.000462	0.00167	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00046	0.00166	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00046	0.00166	CcSEcCtD
Ezogabine—Paraesthesia—Epirubicin—thyroid cancer	0.000456	0.00164	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000454	0.00164	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—thyroid cancer	0.000452	0.00163	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—thyroid cancer	0.000451	0.00163	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—thyroid cancer	0.000447	0.00161	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000438	0.00158	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—thyroid cancer	0.000437	0.00158	CcSEcCtD
Ezogabine—Constipation—Epirubicin—thyroid cancer	0.000434	0.00157	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—thyroid cancer	0.000422	0.00152	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—thyroid cancer	0.000419	0.00151	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—thyroid cancer	0.000418	0.00151	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—thyroid cancer	0.000417	0.00151	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—thyroid cancer	0.000413	0.00149	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000405	0.00146	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—thyroid cancer	0.000405	0.00146	CcSEcCtD
Ezogabine—Constipation—Doxorubicin—thyroid cancer	0.000402	0.00145	CcSEcCtD
Ezogabine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000387	0.0014	CcSEcCtD
Ezogabine—Asthenia—Epirubicin—thyroid cancer	0.000364	0.00131	CcSEcCtD
Ezogabine—Asthenia—Doxorubicin—thyroid cancer	0.000337	0.00122	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—thyroid cancer	0.000336	0.00121	CcSEcCtD
Ezogabine—Rash—Epirubicin—thyroid cancer	0.00032	0.00115	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—thyroid cancer	0.00032	0.00115	CcSEcCtD
Ezogabine—Dizziness—Doxorubicin—thyroid cancer	0.00031	0.00112	CcSEcCtD
Ezogabine—Nausea—Epirubicin—thyroid cancer	0.000301	0.00109	CcSEcCtD
Ezogabine—Rash—Doxorubicin—thyroid cancer	0.000296	0.00107	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—thyroid cancer	0.000296	0.00107	CcSEcCtD
Ezogabine—Nausea—Doxorubicin—thyroid cancer	0.000279	0.00101	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—CHST14—thyroid cancer	0.000258	0.0583	CbGpPWpGaD
Ezogabine—UGT1A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000177	0.0401	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000156	0.0353	CbGpPWpGaD
Ezogabine—UGT1A3—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000147	0.0333	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CHST14—thyroid cancer	0.00013	0.0294	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00013	0.0293	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—RXRA—thyroid cancer	0.00012	0.0272	CbGpPWpGaD
Ezogabine—UGT1A1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000102	0.023	CbGpPWpGaD
Ezogabine—UGT1A9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000102	0.023	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—CHST14—thyroid cancer	8.98e-05	0.0203	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CHST14—thyroid cancer	8.98e-05	0.0203	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—SMUG1—thyroid cancer	8.52e-05	0.0193	CbGpPWpGaD
Ezogabine—CYP2A6—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	7.85e-05	0.0177	CbGpPWpGaD
Ezogabine—NAT2—Biological oxidations—RXRA—thyroid cancer	7.62e-05	0.0172	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—thyroid cancer	6.79e-05	0.0153	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—SLC5A5—thyroid cancer	6.26e-05	0.0142	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—MINPP1—thyroid cancer	5.6e-05	0.0126	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—BRAF—thyroid cancer	5.54e-05	0.0125	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—BRAF—thyroid cancer	5.54e-05	0.0125	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—CCND1—thyroid cancer	5.39e-05	0.0122	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—RXRA—thyroid cancer	5.26e-05	0.0119	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SLC5A5—thyroid cancer	5.21e-05	0.0118	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NDUFA13—thyroid cancer	4.76e-05	0.0108	CbGpPWpGaD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	4.75e-05	0.0107	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—CDK1—thyroid cancer	4.65e-05	0.0105	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—CDK1—thyroid cancer	4.65e-05	0.0105	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—RXRA—thyroid cancer	4.62e-05	0.0104	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—NRG1—thyroid cancer	4.55e-05	0.0103	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CHST14—thyroid cancer	4.48e-05	0.0101	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—RXRA—thyroid cancer	4.38e-05	0.00989	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.85e-05	0.00869	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—RXRA—thyroid cancer	3.84e-05	0.00867	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—RXRA—thyroid cancer	3.79e-05	0.00857	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—NRG1—thyroid cancer	3.78e-05	0.00855	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	3.71e-05	0.00838	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—HPGD—thyroid cancer	3.61e-05	0.00815	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC5A5—thyroid cancer	3.6e-05	0.00813	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC5A5—thyroid cancer	3.6e-05	0.00813	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—MINPP1—thyroid cancer	3.39e-05	0.00766	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CDK1—thyroid cancer	3.32e-05	0.0075	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CDK1—thyroid cancer	3.32e-05	0.0075	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—RXRA—thyroid cancer	3.08e-05	0.00696	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—RXRA—thyroid cancer	3.08e-05	0.00696	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—RXRA—thyroid cancer	3.02e-05	0.00683	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	3.02e-05	0.00683	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—BRAF—thyroid cancer	2.99e-05	0.00676	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—BRAF—thyroid cancer	2.99e-05	0.00676	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NDUFA13—thyroid cancer	2.88e-05	0.00652	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MINPP1—thyroid cancer	2.82e-05	0.00637	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	2.82e-05	0.00637	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC5A5—thyroid cancer	2.77e-05	0.00627	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CHST14—thyroid cancer	2.71e-05	0.00613	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—RXRA—thyroid cancer	2.65e-05	0.00599	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—RXRA—thyroid cancer	2.65e-05	0.00599	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—NRG1—thyroid cancer	2.61e-05	0.00591	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	2.61e-05	0.00591	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	2.56e-05	0.00578	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—HRAS—thyroid cancer	2.55e-05	0.00576	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—HRAS—thyroid cancer	2.55e-05	0.00576	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NDUFA13—thyroid cancer	2.4e-05	0.00542	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	2.39e-05	0.00541	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	2.34e-05	0.00529	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—RXRA—thyroid cancer	2.33e-05	0.00527	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—thyroid cancer	2.26e-05	0.00512	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CHST14—thyroid cancer	2.25e-05	0.00509	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—HPGD—thyroid cancer	2.19e-05	0.00494	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TPR—thyroid cancer	2.07e-05	0.00468	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—RXRA—thyroid cancer	2.04e-05	0.00462	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PRKAR1A—thyroid cancer	2.04e-05	0.00461	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—NRG1—thyroid cancer	2.02e-05	0.00455	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MINPP1—thyroid cancer	1.95e-05	0.0044	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MINPP1—thyroid cancer	1.95e-05	0.0044	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PPARG—thyroid cancer	1.94e-05	0.00439	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PPARG—thyroid cancer	1.94e-05	0.00439	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—HPGD—thyroid cancer	1.82e-05	0.00411	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—NRAS—thyroid cancer	1.67e-05	0.00377	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—NRAS—thyroid cancer	1.67e-05	0.00377	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NDUFA13—thyroid cancer	1.66e-05	0.00374	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NDUFA13—thyroid cancer	1.66e-05	0.00374	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	1.61e-05	0.00365	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CHST14—thyroid cancer	1.56e-05	0.00352	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CHST14—thyroid cancer	1.56e-05	0.00352	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SLC5A5—thyroid cancer	1.55e-05	0.0035	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MINPP1—thyroid cancer	1.5e-05	0.00339	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KRAS—thyroid cancer	1.44e-05	0.00324	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—KRAS—thyroid cancer	1.44e-05	0.00324	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—HRAS—thyroid cancer	1.38e-05	0.00311	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—HRAS—thyroid cancer	1.38e-05	0.00311	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—RXRA—thyroid cancer	1.3e-05	0.00294	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NDUFA13—thyroid cancer	1.28e-05	0.00289	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TPR—thyroid cancer	1.26e-05	0.00284	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—HPGD—thyroid cancer	1.26e-05	0.00284	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—HPGD—thyroid cancer	1.26e-05	0.00284	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PRKAR1A—thyroid cancer	1.23e-05	0.00279	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—HRAS—thyroid cancer	1.22e-05	0.00276	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—HRAS—thyroid cancer	1.22e-05	0.00276	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CHST14—thyroid cancer	1.2e-05	0.00271	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NRAS—thyroid cancer	1.19e-05	0.00269	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NRAS—thyroid cancer	1.19e-05	0.00269	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TPR—thyroid cancer	1.04e-05	0.00236	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PRKAR1A—thyroid cancer	1.03e-05	0.00232	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—thyroid cancer	1.02e-05	0.00232	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—thyroid cancer	1.02e-05	0.00232	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.02e-05	0.0023	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HPGD—thyroid cancer	9.68e-06	0.00219	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SLC5A5—thyroid cancer	9.4e-06	0.00212	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—thyroid cancer	8.71e-06	0.00197	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—thyroid cancer	8.71e-06	0.00197	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPARG—thyroid cancer	8.23e-06	0.00186	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RXRA—thyroid cancer	7.89e-06	0.00178	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC5A5—thyroid cancer	7.81e-06	0.00176	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—thyroid cancer	7.69e-06	0.00174	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—thyroid cancer	7.69e-06	0.00174	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TPR—thyroid cancer	7.21e-06	0.00163	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TPR—thyroid cancer	7.21e-06	0.00163	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PRKAR1A—thyroid cancer	7.09e-06	0.0016	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	7.09e-06	0.0016	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RXRA—thyroid cancer	6.56e-06	0.00148	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—thyroid cancer	6.47e-06	0.00146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.43e-06	0.00145	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—thyroid cancer	5.64e-06	0.00128	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TPR—thyroid cancer	5.56e-06	0.00126	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PRKAR1A—thyroid cancer	5.47e-06	0.00124	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC5A5—thyroid cancer	5.4e-06	0.00122	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC5A5—thyroid cancer	5.4e-06	0.00122	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.06e-06	0.00114	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARG—thyroid cancer	4.98e-06	0.00113	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RXRA—thyroid cancer	4.53e-06	0.00102	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RXRA—thyroid cancer	4.53e-06	0.00102	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.41e-06	0.000997	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC5A5—thyroid cancer	4.16e-06	0.00094	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARG—thyroid cancer	4.14e-06	0.000936	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—thyroid cancer	3.92e-06	0.000886	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RXRA—thyroid cancer	3.5e-06	0.00079	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—thyroid cancer	3.42e-06	0.000773	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—thyroid cancer	3.26e-06	0.000737	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—thyroid cancer	3.25e-06	0.000735	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARG—thyroid cancer	2.86e-06	0.000647	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARG—thyroid cancer	2.86e-06	0.000647	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—thyroid cancer	2.84e-06	0.000642	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—thyroid cancer	2.25e-06	0.000509	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—thyroid cancer	2.25e-06	0.000509	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARG—thyroid cancer	2.21e-06	0.000499	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—thyroid cancer	1.97e-06	0.000445	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—thyroid cancer	1.96e-06	0.000444	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—thyroid cancer	1.96e-06	0.000444	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—thyroid cancer	1.74e-06	0.000392	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—thyroid cancer	1.64e-06	0.00037	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—thyroid cancer	1.51e-06	0.000342	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—thyroid cancer	1.13e-06	0.000256	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—thyroid cancer	1.13e-06	0.000256	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—thyroid cancer	8.73e-07	0.000197	CbGpPWpGaD
